Ananda Scientific · Clinical-stage pharma
A clinical-stage pharma company rebuilding the standard of care for PTSD.
Twenty-five years since the last FDA-approved PTSD monotherapy. Nantheia™ is in five active Phase II trials across four academic medical centers. The pivotal PTSD trial is scheduled to initiate Q1 2027, read out Q3 2028, with NDA filing Q4 2028 and product launch Q4 2029.
The void
Twenty-five years. No new monotherapy for PTSD.
The FDA has approved exactly two monotherapies for PTSD — sertraline in 1999 and paroxetine in 2001. Both are SSRIs repurposed from depression, with response rates of 37–62%. For the 13 million Americans living with PTSD, the standard of care is older than the iPhone.
The monotherapy void · 25+ years
The platform
The bioavailability wall, solved.
Liquid Structure™ is a patented, pharmaceutical-quality delivery technology invented at Hebrew University and exclusively licensed to Ananda. It forms self-emulsifying nano-domains that achieve higher Cmax, shorter Tmax, and no food effect versus FDA-approved Epidiolex®.
Read the science →Fig. 03 · Plasma exposure (illustrative)
Nantheia™ vs Epidiolex® — single oral dose
- Cmax vs Epidiolex®
- ~1.95× higher · single oral dose
- Tmax
- ~57% shorter · faster, predictable onset
- Inter-subject CV
- ~75% across Nantheia™ arms vs ~308% (Epidiolex® label)
- Dose-linearity
- Linear PK across 200 mg and 400 mg doses
- Food effect
- None observed, high-fat vs regular-fat
- Shelf stability
- 4+ years at ambient
- Manufacturing
- cGMP softgel · pharma CMO
Source: Phase I PK study · 24-subject crossover · single oral dose · high-fat vs regular-fat arms · data on file.
Clinical pipeline
Five Phase II programs. One platform.
A focused portfolio in neuropsychiatric and neurodegenerative disease, run with NYU Langone, UCLA, Yale, and UNMC. Every trial under FDA-approved IND, with $17M in grant funding awarded to investigators.
Full pipeline detail →Post-traumatic stress disorder
Nantheia™ ATL5
13M adults · US · $16B global
Social anxiety disorder
Nantheia™ A1002
15M adults · US · $11.6B global
Opioid use disorder
Nantheia™ ATL5
9.3M adults · US · $3.93B global
Smoking cessation
Nantheia™ ATL5
US adults
Childhood epilepsy
Nantheia™ ATL5
$4.2B childhood epilepsy · $12.3B global epilepsy
Alzheimer's disease
Nantheia™ ATL5
US adults
Lead program · PTSD
Built for the disease. Not borrowed from depression.
PTSD is heterogeneous — four cardinal symptom domains and frequent comorbidities. Nantheia™ CBD is multifactorial by design, developed specifically for PTSD rather than repurposed from depression.
PTSD program detail →DSM-5 · Four cardinal symptom domains
Intrusive
Unwanted thoughts · nightmares · flashbacks
Avoidance
Of trauma-associated stimuli, activities, people
Mood
Negative mood · excessive guilt · reduced interest
Hyper-arousal
Heightened startle · sleep disturbance · insomnia
Purpose-built for PTSD
Developed for trauma physiology — not repurposed from depression like SSRIs and SNRIs.
Multifactorial mechanism
CBD acts at multiple receptors implicated across the trauma response — distinct from single-target SSRIs.
Differentiated PK
Liquid Structure™ delivers higher Cmax and shorter Tmax than reference CBD formulations.
Safety profile
CBD has an established safety record across prior clinical use and ongoing Phase II trials.
Path to launch
Eleven catalysts. To NDA, to launch.
A capital-efficient regulatory and commercial roadmap. Phase II readouts begin Q2 2026; pivotal initiation Q1 2027; pivotal readout Q3 2028; NDA filing Q4 2028; PTSD product launch Q4 2029.
Full timeline →- Q1 2026NYU Phase IIa SAD readout (N=60) — available under CDACOMPLETED
- Q2 2026NYU Langone Phase II PTSD readout (N=85)TIER-1 READOUT
- Q2 2026Nebraska Phase II PTSD interim readoutINTERIM
- Q4 2026UCLA Smoking Cessation Phase II final readoutREADOUT
- Q4 2026FDA Pivotal Trial Initiation MeetingREGULATORY
- Q1 2027Multi-center pivotal PTSD trial initiation (N=350)TRIAL START
- Q1 2027Nebraska Phase II PTSD final readout (N=140)READOUT
- Q1 2027Yale Phase II OUD readout (N=120)READOUT
- Q3 2028Pivotal PTSD trial readout (N=350)PIVOTAL READOUT
- Q4 2028NDA filing with FDAFILING
- Q4 2029PTSD product launchAPPROVAL
Collaborators
Run with the field's leading investigators.
Four academic medical centers and $17M in NIH and other grant funding awarded directly to investigator-led programs.
Investigators & SAB →Scientific Advisory Board · Three of the most-cited names in PTSD
Investor relations · Q2 2026
The first new PTSD monotherapy in 25+ years is closer than you think.
Series B+ is open with a $50M target to advance the pivotal PTSD trial. Diligence packages and Phase II data available under CDA.